What drove the pre-market move in AYA.AX stock today?

AYA.AX stock fell **9.97%** pre-market to **A$3.07** on lighter volume and profit taking after recent gains. Overbought technicals and positioning ahead of the 24 Feb 2026 earnings date likely amplified selling.

What is Meyka AI’s short and long term forecast for AYA.AX?

Meyka AI's model lists a monthly forecast **A$3.56**, quarterly **A$5.83** and 12‑month **A$7.90**, implying about **157.44%** upside from **A$3.07**; forecasts are projections, not guarantees.

How do Artrya’s financials affect AYA.AX valuation?

Artrya has EPS **-0.18**, cash per share **A$0.11**, and a high PB of **15.00**, which make valuation sensitive to revenue growth and margin improvement as the company commercialises Salix.

Should I trade AYA.AX around the upcoming earnings?

Earnings on 24 Feb 2026 can trigger volatility. Short‑term traders may watch volume and RSI; longer‑term investors should prioritise adoption milestones, recurring revenue signs and regulatory updates before adding exposure.

AU Stocks

AYA.AX stock down 9.97% pre-market 17 Feb 2026: AI diagnostics outlook

ByHuzaifa Zahoor February 16, 2026February 16, 2026

AYA.AX stock opened pre-market at A$3.07, down 9.97% from the previous close after intraday trading showed a low of A$3.01 and volume of 372,628 shares. Investors are weighing Artrya Limited’s AI diagnostic traction for coronary disease against stretched valuation multiples and upcoming earnings on 24 Feb 2026. Today’s move reflects profit-taking after recent gains and signals rising short-term volatility as technical indicators show overbought readings while longer-term averages remain mixed. We examine fundamentals, technicals and Meyka AI forecasts to frame a risk-reward view for Australian AI healthcare exposure on the ASX.